NCT01584284View on ClinicalTrials.gov

Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

July 31, 2015

Conditions

Cancer of Head and Neck

Interventions

BIOLOGICAL

GL-ONC1

A genetically-engineered vaccinia virus administered via intravenous infusion . Cohorts 1, 2, 3: Frequency: 1x in Week 1; Cohort 4: 1x again 1x in Week 2; Cohort 5: 1x Week 1, 1x Week 2, 1x Week 3, 1x Week 4.

Trial Locations (1)

92037

Moores UC San Diego Cancer Center, La Jolla